Dec. 19 at 2:19 PM
$HOWL Analyst Jason Zemansky of Bank of America Securities maintained a Buy rating on HOWL, retaining the price target of
$7.00. He has given his Buy rating due to a combination of factors tied to Werewolf Therapeutics’ clinical progress and technology platform. He highlights that recent data for the company’s masked IL‑2 (WTX‑124) and IL‑12 (WTX‑330) candidates support both the underlying biology of the cytokines and the masking approach, which appears to mitigate historical safety concerns. In IL‑2 monotherapy, he notes that objective response rates in a heavily pretreated population compare favorably with typical outcomes seen when patients are simply re-exposed to immune checkpoint inhibitors, and he sees additional upside from future combination regimens. He also emphasizes that despite a sharp share price decline driven by disappointment over limited combination data disclosures, the fundamental efficacy & safety signals remain positive, and the market reaction seems excessive.
